id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-331428-6pvr2vew	Heffernan, Kevin S.	Exercise as medicine for COVID-19: on PPAR with emerging pharmacotherapy	2020-08-17		.txt	text/plain	1835	107	34	Emerging studies suggest that SARS-CoV-2 alters lipid metabolism in the lung epithelial cells by modulating peroxisome proliferator-activated receptor alpha (PPARα), possibly contributing to lipotoxicity, inflammation and untoward respiratory effects. While we all eagerly await the development of a vaccine, scientists and clinicians have begun exploring "off-label" use of various drugs with that hope that strategic repurposing may help manage and treat COVID-19.(1) Fenofibrate (a peroxisome proliferator-activated receptor alpha agonist) is one such medication that holds promise given its favorable effects on inflammation and endothelial function. This paper will explore the hypothesis that exercise may be a useful adjuvant in a setting of COVID-19 management/rehabilitation due to its effects on PPAR and vascular endothelial function. (3) Emerging studies suggest that SARS-CoV-2 alters lipid metabolism in the lung epithelial cells by modulating PPAR, possibly contributing to lipotoxicity and untoward respiratory effects. Peroxisome Proliferator-Activated Receptor α Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial Cells	./cache/cord-331428-6pvr2vew.txt	./txt/cord-331428-6pvr2vew.txt